Stockpolly
Search
MAZE · NASDAQ · Biotechnology

Maze (MAZE)

Develops small-molecule therapies guided by human genetics for kidney and metabolic diseases.

$26.70
At close+0.17 (+0.64%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000165300000200
Cost of revenue000000010000
Gross profit000165300−100200
252328252730353633384648
Research & development191622202022282825283435
676678888101213
General & administrative676678888101213
Other expenses0000000−10000
Operating income−25−23−28140−24−30−35−36−33−38−27−48
0−4−41−10333323
Interest income000122333330
Interest expense000000000011
Other non-operating income044−110−3−3−3−3−3−4
Income before tax−25−27−32141−25−30−33−34−30−35−24−45
Income tax expense000200000000
Net income from continuing operations−25−27−32139−25−30−33−34−30−35−24−45
Net income−25−27−32139−25−30−33−34−30−35−24−45
EPS, basic−$0.57−$0.61−$0.74$0.98−$0.06−$0.11−$0.75−$0.77−$0.66−$0.87−$0.45−$0.76
EPS, diluted−$0.57−$0.61−$0.74$0.98−$0.06−$0.11−$0.75−$0.77−$0.66−$0.87−$0.45−$0.76
Weighted average shares, basic444444444444444446435459
Weighted average shares, diluted444444444444444446435459
EBITDA−24−26−32142−24−29−32−33−30−34−23−44
Depreciation & amortization111111111000
EBIT−25−27−32141−25−30−33−34−30−35−23−44